These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 10451163)

  • 21. Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine.
    Stover CK; Bansal GP; Hanson MS; Burlein JE; Palaszynski SR; Young JF; Koenig S; Young DB; Sadziene A; Barbour AG
    J Exp Med; 1993 Jul; 178(1):197-209. PubMed ID: 8315378
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of immunization with recombinant OspA on serologic tests for Lyme borreliosis.
    Fawcett PT; Rose CD; Budd SM; Gibney KM
    Clin Diagn Lab Immunol; 2001 Jan; 8(1):79-84. PubMed ID: 11139199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vaccination against lyme disease with recombinant Borrelia burgdorferi outer-surface protein A (rOspA) in horses.
    Chang Y; Novosol V; McDonough SP; Chang CF; Jacobson RH; Divers T; Quimby FW; Shin S; Lein DH
    Vaccine; 1999 Oct; 18(5-6):540-8. PubMed ID: 10519945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization and optimization of a novel vaccine for protection against Lyme borreliosis.
    Comstedt P; Hanner M; Schüler W; Meinke A; Schlegl R; Lundberg U
    Vaccine; 2015 Nov; 33(44):5982-8. PubMed ID: 26277070
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunization with a recombinant subunit OspA vaccine markedly impacts the rate of newly acquired Borrelia burgdorferi infections in client-owned dogs living in a coastal community in Maine, USA.
    Eschner AK; Mugnai K
    Parasit Vectors; 2015 Feb; 8():92. PubMed ID: 25890386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral vaccination with an attenuated Salmonella typhimurium strain expressing Borrelia burgdorferi OspA prevents murine Lyme borreliosis.
    Dunne M; al-Ramadi BK; Barthold SW; Flavell RA; Fikrig E
    Infect Immun; 1995 Apr; 63(4):1611-4. PubMed ID: 7890431
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Broadly Protective Multivalent OspA Vaccine against Lyme Borreliosis, Developed Based on Surface Shaping of the C-Terminal Fragment.
    Nayak A; Schüler W; Seidel S; Gomez I; Meinke A; Comstedt P; Lundberg U
    Infect Immun; 2020 Mar; 88(4):. PubMed ID: 31932330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral delivery of purified lipoprotein OspA protects mice from systemic infection with Borrelia burgdorferi.
    Luke CJ; Huebner RC; Kasmiersky V; Barbour AG
    Vaccine; 1997; 15(6-7):739-46. PubMed ID: 9178476
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recombinant assay for serodiagnosis of Lyme disease regardless of OspA vaccination status.
    Gomes-Solecki MJ; Wormser GP; Schriefer M; Neuman G; Hannafey L; Glass JD; Dattwyler RJ
    J Clin Microbiol; 2002 Jan; 40(1):193-7. PubMed ID: 11773115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protective efficacy of an oral vaccine to reduce carriage of Borrelia burgdorferi (strain N40) in mouse and tick reservoirs.
    Scheckelhoff MR; Telford SR; Hu LT
    Vaccine; 2006 Mar; 24(11):1949-57. PubMed ID: 16300863
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial.
    Wressnigg N; Pöllabauer EM; Aichinger G; Portsmouth D; Löw-Baselli A; Fritsch S; Livey I; Crowe BA; Schwendinger M; Brühl P; Pilz A; Dvorak T; Singer J; Firth C; Luft B; Schmitt B; Zeitlinger M; Müller M; Kollaritsch H; Paulke-Korinek M; Esen M; Kremsner PG; Ehrlich HJ; Barrett PN
    Lancet Infect Dis; 2013 Aug; 13(8):680-9. PubMed ID: 23665341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incomplete protection of hamsters vaccinated with unlipidated OspA from Borrelia burgdorferi infection is associated with low levels of antibody to an epitope defined by mAb LA-2.
    Johnson BJ; Sviat SL; Happ CM; Dunn JJ; Frantz JC; Mayer LW; Piesman J
    Vaccine; 1995 Aug; 13(12):1086-94. PubMed ID: 7491816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recombinant OspA protects dogs against infection and disease caused by Borrelia burgdorferi.
    Chang YF; Appel MJ; Jacobson RH; Shin SJ; Harpending P; Straubinger R; Patrican LA; Mohammed H; Summers BA
    Infect Immun; 1995 Sep; 63(9):3543-9. PubMed ID: 7642289
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neurological complications of vaccination with outer surface protein A (OspA).
    Marks DH
    Int J Risk Saf Med; 2011; 23(2):89-96. PubMed ID: 21673416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Abilities of OspA proteins from different seroprotective groups of Borrelia burgdorferi to protect hamsters from infection.
    Lovrich SD; Callister SM; DuChateau BK; Lim LC; Winfrey J; Day SP; Schell RF
    Infect Immun; 1995 Jun; 63(6):2113-9. PubMed ID: 7768589
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospects for a vaccine to prevent Lyme disease in humans.
    Wormser GP
    Clin Infect Dis; 1995 Nov; 21(5):1267-74. PubMed ID: 8589153
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reactivity with a specific epitope of outer surface protein A predicts protection from infection with the Lyme disease spirochete, Borrelia burgdorferi.
    Golde WT; Piesman J; Dolan MC; Kramer M; Hauser P; Lobet Y; Capiau C; Desmons P; Voet P; Dearwester D; Frantz JC
    Infect Immun; 1997 Mar; 65(3):882-9. PubMed ID: 9038292
    [TBL] [Abstract][Full Text] [Related]  

  • 38. OspA lipoprotein of Borrelia burgdorferi is a mucosal immunogen and adjuvant.
    Erdile LF; Guy B
    Vaccine; 1997 Jun; 15(9):988-96. PubMed ID: 9261945
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Lyme disease vaccine candidate outer surface protein A (OspA) in a formulation compatible with human use protects mice against natural tick transmission of B. burgdorferi.
    Golde WT; Burkot TR; Piesman J; Dolan MC; Capiau C; Hauser P; Dequesne G; Lobet Y
    Vaccine; 1995 Apr; 13(5):435-41. PubMed ID: 7639011
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasmid DNA and protein vaccination of mice to the outer surface protein A of Borrelia burgdorferi leads to induction of T helper cells with specificity for a major epitope and augmentation of protective IgG antibodies in vivo.
    Zhong W; Wiesmüller KH; Kramer MD; Wallich R; Simon MM
    Eur J Immunol; 1996 Nov; 26(11):2749-57. PubMed ID: 8921965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.